Cargando…

Abiraterone Rechallenge Based on Sequential Testing of Androgen Receptor Splice Variant 7 Expression in Circulating Tumor Cells: A Case Report

Serial analysis of circulating tumor cells (CTCs) such as androgen receptor splice variant 7 is useful in selecting treatments for castration-resistant prostate cancer (CRPC). We report a case who had been positive for androgen receptor splice variant 7 in CTCs before docetaxel, and was subsequently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagaya, Naoya, Kanayama, Mayuko, Nagata, Masayoshi, Horie, Shigeo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179658/ https://www.ncbi.nlm.nih.gov/pubmed/32373521 http://dx.doi.org/10.3389/fonc.2020.00495

Ejemplares similares

The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma
por: Nagaya, Naoya, et al.
Publicado: (2018)

Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer
por: Ashizawa, Takeshi, et al.
Publicado: (2022)

Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
por: Nagaya, Naoya, et al.
Publicado: (2020)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

Transcription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer
por: Nagaya, Naoya, et al.
Publicado: (2021)

Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor
por: Hu, Zengchun, et al.
Publicado: (2021)

Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer
por: He, Yundong, et al.
Publicado: (2018)

Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
por: Kattan, Michael W., et al.
Publicado: (2020)

T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
por: Kobayashi, Takuro, et al.
Publicado: (2023)

Androgen-Receptor Positive Lacrimal Sac Adenocarcinoma Demonstrating Long-Lasting Response to LHRH Analog Plus Abiraterone Treatment
por: Vagia, Elena, et al.
Publicado: (2015)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

The positive relationship between androgen receptor splice variant-7 expression and the risk of castration-resistant prostate cancer: A cumulative analysis
por: Zhao, Shankun, et al.
Publicado: (2023)

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wang, Jiaxin, et al.
Publicado: (2020)

Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy
por: Ohtaka, Ayako, et al.
Publicado: (2019)

Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis
por: Matsumura, Naoki, et al.
Publicado: (2021)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

AR Splicing Variants and Resistance to AR Targeting Agents
por: Kanayama, Mayuko, et al.
Publicado: (2021)

The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis
por: Wang, Zhize, et al.
Publicado: (2020)

Choice of antibody is critical for specific and sensitive detection of androgen receptor splice variant-7 in circulating tumor cells
por: Khan, Tanzila, et al.
Publicado: (2022)

Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol
por: Clark, Emma, et al.
Publicado: (2019)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
por: Wright, Timothy C., et al.
Publicado: (2021)

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
por: Chen, Ming-kun, et al.
Publicado: (2022)

Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases
por: Hirano, Hisashi, et al.
Publicado: (2023)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Decoding the androgen receptor splice variants
por: Lu, Changxue, et al.
Publicado: (2013)

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
por: Moll, J. Matthijs, et al.
Publicado: (2022)

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
por: Liu, Chengfei, et al.
Publicado: (2016)

Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters
por: Sharova, Evgeniya, et al.
Publicado: (2021)

A retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergy
por: Thong, Bernard Yu-Hor, et al.
Publicado: (2014)

Generation of transgenic mouse line with prostate-specific expression of codon-improved Cre recombinase
por: Kanayama, Mayuko, et al.
Publicado: (2018)

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer
por: Miller, Katie Joanna, et al.
Publicado: (2023)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2023)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
por: Ning, Wei, et al.
Publicado: (2023)

Androgen Receptor Splicing Variant-7 in Breast Cancer: Clinical and Pathologic Correlations
por: Ferguson, Donna C., et al.
Publicado: (2022)

Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review
por: Pierantoni, Francesco, et al.
Publicado: (2019)

Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
por: Mariani, Stefano, et al.
Publicado: (2022)

Biotransformation of Abiraterone Into Five Characteristic Metabolites by the Rat Gut Microbiota and Liver Microsomes
por: Keranmu, Adili, et al.
Publicado: (2022)

Splice Variants of Androgen Receptor and Prostate Cancer
por: Caffo, Orazio, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0ca7v5572ht1qtm7p09s67v1ar